In the context of drug development, the average phase 3 duration is approximately 2.5 years. It's clear folks want to make investments in technologies and capabilities that allow for quicker advancements if medicines. Can AI help?
Find out in our latest webinar: https://vibebio.com/resources/events/how-ai-analysis-supports-drug-dev/
